Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona Ancona, Italy
  • Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati Aviano, Italy
  • A.O. Spedali Civili di Brescia - Ematologia Brescia, Italy
  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia Florence, Italy
View all 18 locations
View Trial Details
Recruiting

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

NCT07620275

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Biotherapeutic Department of Chinese PLA General Hospital Beijing, Beijing Municipality, China
  • Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China
  • National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin, China
View Trial Details
Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

NCT05557695

Conditions
Chronic Lymphocytic Leukemia, CLL, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Research Site Aylesbury, United Kingdom
  • Research Site Bath, United Kingdom
  • Research Site Birmingham, United Kingdom
  • Research Site Bournemouth, United Kingdom
View all 29 locations
View Trial Details
Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

NCT05231629

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Columbia University New York, United States
  • Oregon Health and Science University Portland, Oregon, United States
View Trial Details
Recruiting

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304

Conditions
Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, +13 more
Locations
  • University of Miami Miller School of Medicine Miami, Florida, United States
  • University of Illinois at Chicago Chicago, Illinois, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

NCT05929222

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico Sassuolo, Modena (MO), Italy
  • Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo, SCDU Ematologia Alessandria, Italy
  • AORN San Giuseppe Moscati Avellino, U.O.C. Ematologia e Trapianto Emopoietico Avellino, Italy
  • Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati Aviano, Italy
View all 49 locations
View Trial Details
Recruiting

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

NCT06918002

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHU Amiens Amiens, France
  • CHU Angers Angers, France
  • Ch Annecy Genevois Annecy, France
  • Centre Hospitalier d'Argenteuil Victor Dupouy Argenteuil, France
View all 64 locations
View Trial Details

Related conditions